Drug Trial Radar · NCT06932003
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jul 8, 2025
Primary completion
Oct 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase Ic/II clinical trial conducted in Chinese patients with moderate-to-severe hidradenitis suppurativa (HS), aiming to evaluate the safety and efficacy of LT-002-158 tablets in the treatment of moderate-to-severe HS. The study consists of two parts. The Phase Ic portion employs an open-label, single-arm design to primarily investigate the safety and tolerability of LT-002-158 tablets in patients with moderate-to-severe HS. The Phase II study adopts a randomized, double-blind, placebo-controlled, parallel-group design, with an open-label, single-arm extension phase, to primarily assess the therapeutic efficacy of LT-002-158 tablets in patients with moderate-to-severe HS.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
LT-002-158 TabletsDrug
The subjects will orally administered LT-002-158 tablets once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment emergent Adverse EventsTime frame: Day 1-Day 42
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.